Who owns KLRA?
Institutional ownership of Kailera Therapeutics Inc. from Form 13F, Q2 2026
99 institutional managers reported holding Kailera Therapeutics Inc. (KLRA) in Form 13F filings for Q2 2026, with 116,154,321 shares worth $2.6B. The largest reported holder was Bain Capital Investors LLC. 98 opened new positions and 0 sold out.
- Funds holding
- 99
- Value held
- $2.6B
- New / sold out
- 98 / 0
- Net shares, same filers
- None
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of KLRA
Share of 13F holdings is each fund's shares as a share of the 116,154,321 KLRA shares all 13F filers reported, not of shares outstanding.
Schedule 13D and 13G filings on KLRA
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-08-14RTW INVESTMENTS, LP SCHEDULE 13G filed by Kailera Therapeutics Inc.Schedule 13G
- 2026-08-05Jiangsu Hengrui Pharmaceuticals Co., Ltd. SCHEDULE 13G filed by Kailera Therapeutics Inc.Schedule 13G
- 2026-04-24BCLS Fund IV Investments, L.P. SCHEDULE 13D filed by Kailera Therapeutics Inc.Schedule 13D
- 2026-04-23BCPE Perseus Investor, LP SCHEDULE 13D filed by Kailera Therapeutics Inc.Schedule 13D
Questions about KLRA ownership
- Who owns KLRA stock?
- 99 institutional investment managers reported KLRA positions in their Form 13F filings for Q2 2026, holding 116,154,321 shares worth $2.6B in total. Bain Capital Investors LLC reported the largest position.
- Are funds buying or selling KLRA?
- 98 managers opened new KLRA positions in Q2 2026.
- How current is this KLRA institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to KLRA by CUSIP. Options are left out. KLRA news and filings · KLRA insider trades · Top funds